Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spikevax post-vaccination serious adverse event follow-up survey in Japan
jRCT2031210168Active, not recruiting
- Sponsor
- Takeda
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Takeda. Primary endpoint: Percentage of participants with serious adverse events. Started Dec 2021; status: active, not recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210168.